Hydrix eyes Indian med-device cos for tech-transfer to develop products in POC diagnostics
Hydrix from Carnegie is now looking at tapping opportunities in technology transfer and joint product development for range of point-of-care (POC) diagnostics with companies in India.The company is a mobile-wireless technology major and an award winner for developing innovative systems covering implantable, insertables, wearables, in-vitro diagnostics, point of care and laboratory test equipment.
Hydrix from Carnegie, a suburb in the State of Victoria, Australia, a leading software and electronic design consultancy, is now looking at tapping opportunities in technology transfer and joint product development for range of point-of-care (POC) diagnostics with companies in India. The company is a mobile-wireless technology major and an award winner for developing innovative systems covering implantable, insertables, wearables, in-vitro diagnostics, point of care and laboratory test equipment.
Currently, India imports 70 per cent of its diagnostics from various countries and the high rate of custom duty has been detrimental to its indigenous manufacturers. Moreover, the country is home to a large diabetic population estimated at 61 million and there is an increasing incidence of life style disorders including hypertension and cardiovascular disease which requires POC diagnostics. The infusion of embedded technology in diagnostics can revolutionize healthcare in India.
“This is where Hydrix, is keen to chip in its expertise so as to help the Indian medical device industry come out with advanced diagnostics that would help its people in the far-flung remote villages to monitor their health parameters,” Peter Lewis, director, business development, Hydrix told Pharmabiz at the sidelines of interaction.
“India’s domination in information technology and large number of cell phone users, vast population and growing incidence of diseases has created a need for quick tests for early treatment protocols. With a decade of experience, we are now assessing the Indian market to understand the medical device industry and patient needs to tap the opportunities,” he added.
Specifically in India, we are looking at point-of-care and laboratory test equipment. There is also a huge opportunity to develop implantables too. Since, there is an impressive base of nine million cell phone subscribers in a country with 1.2 billion population, we could develop a technology that can be linked to the mobile to test and report the information including ECG to the closest hospitals, said Lewis.
The Indian medical technology industry can build its revenues from its domestic market with advanced and easy to use point of care systems. Hydrix can provide the high quality design software known for both functionality and regulatory compliance like FDA-510K, PMA and De Novo, CE and TGA design for production transfer and validation.
Hydrix has also interacted with over 25 companies in India which are a combination of start-ups and established players to look at collaborations or joint ventures. Considerable interest is evinced and we are hoping these discussions would get converted into potential business deals, said Lewis.
The size of the medical devices sector in Australia is estimated at Aus$ 300 million and Indian market for the same is valued at $2.5 billion in 2012.
The global slowdown of 2009 had impacted for a while but from 2012, there has been an increase in investments by 30 per cent. Even the Victorian Government under its Market Validation Programme has provided an Aus$ 20 million grant for three years for medical devices R&D, said Lewis.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance